Navigation Links
FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
Date:3/2/2010

Condition known as benign prostatic hyperplasia common in older men

SILVER SPRING, Md., March 2 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The most common symptoms of BPH include a weak stream during urination, urgency, leaking or dribbling, as well as more frequent urination, especially at night.

BPH is common among older men. According to the National Institutes of Health, it rarely causes symptoms before age 40, but more than half of men in their 60s and as many as 90 percent of men older than 70 have BPH symptoms.

"The approval of generic tamsulosin offers greater access to a widely used treatment for BPH," said Gary Buehler, director of the FDA's Office of Generic Drugs. "FDA is committed to making generic drugs available to patients and these drugs meet the same rigid standards as the brand name drugs."

The prescribing information and safety warnings for the generic version of tamsulosin are the same as those for Flomax Capsules. Generic tamsulosin capsules are manufactured by IMPAX Laboratories Inc. of Haywood, Calif. Information about the marketing and availability of this generic drug can be obtained from the manufacturer.

For more information

Consumer Information: Generic Drugs

http://www.fda.gov/Drugs/ResourcesForYou/ucm167906.htm

What BPH Means to Men – A Healthy Moments Podcast from the National Institutes of Health

http://www2.niddk.nih.gov/HealthEducation/HealthyMoments/04_06_2009.htm

Information on specific drug products, Drugs@FDA

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
2. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
3. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
4. FDA Approves Xiaflex for Debilitating Hand Condition
5. FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
6. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
7. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
8. FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
9. FDA Approves Lillys ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
10. FDA Approves Lillys Zyprexa for Two Adolescent Indications
11. US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Summary Provides understanding and ... entered into by the worlds leading healthcare companies. ... Description The Global Atherosclerosis Partnering Terms and ... to partnering deals and agreements entered into by ... Trends in partnering deals - Top deals ...
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... deals and agreements entered into by the worlds leading ... Description The Global Motor Neurone Disease Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
(Date:2/22/2017)... , February 22, 2017 ... microscopy market are Olympus Corporation, Nikon Corporation, and ... or 75% in the overall market in 2015. ... product innovation through result-oriented research and development activities ... expected to focus on expanding their business to ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has lived his ... to spiritually evolve, which is the purpose of everyone in this universe. As Gutierrez ... (published by Balboa Press) attempts to guide readers to expand one’s spiritual life. , ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company that ... its products are coming soon to Amazon.com, the world’s largest online retailer. ... means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been ...
(Date:2/22/2017)... MD (PRWEB) , ... February 22, 2017 , ... ... Direct secure messaging services to the largest network of hospitals, health information ... the National Coordinator for Health Information Technology (ONC-HIT) 2015 Edition Health IT Module ...
(Date:2/22/2017)... CRANBURY, N.J. (PRWEB) , ... February 22, 2017 ... ... than a one-size-fits-all approach, leads to fewer trips the emergency room, fewer hospital ... in The American Journal of Managed Care® (AJMC®) finds. The study can be ...
Breaking Medicine News(10 mins):